|
Hematology:
hemolytic anemia Gastrointestinal:
flatulence, dry mouth or throat, constipation, gastrointestinal hemorrhage, pancreatitis, abnormal liver function tests Nervous/Psychiatric:
somnolence, vertigo, syncope, nervousness, depression, insomnia, paresthesia Text Continues Below
Integumentary:
alopecia, increased sweating, pemphigus, pruritus, exfoliative dermatitis, photosensitivity reaction, dermatopolymyositis Urogenital:
urinary tract infection, impotence, acute renal failure, worsening renal failure Respiratory:
eosinophilic pneumonitis Other:
amblyopia, edema, arthralgia, pharyngitis, agranulocytosis, hepatitis, thrombocytopenia Fetal/Neonatal Morbidity and Mortality
See WARNINGS, Fetal/Neonatal Morbidity and Mortality. Angioedema Angioedema has been reported in patients receiving ACCUPRIL (0.1%). Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis, and/or larynx occurs, treatment with ACCUPRIL should be discontinued and appropriate therapy instituted immediately. (See WARNINGS.) Clinical Laboratory Test Findings Hematology: (See WARNINGS) Hyperkalemia: (See PRECAUTIONS) Creatinine and Blood Urea Nitrogen: Increases (>1.25 times the upper limit of normal) in serum creatinine and blood urea nitrogen were observed in 2% and 2%, respectively, of all patients treated with ACCUPRIL alone. Increases are more likely to occur in patients receiving concomitant diuretic therapy than in those on ACCUPRIL alone. These increases often remit on continued therapy. In controlled studies of heart failure, increases in blood urea nitrogen and serum creatinine were observed in 11% and 8%, respectively, of patients treated with ACCUPRIL; most often these patients were receiving diuretics with or without digitalis. OVERDOSAGE No data are available with respect to overdosage in humans. Doses of 1440 to 4280 mg/kg of quinapril cause significant lethality in mice and rats. Page: << Prev | 1 | 2 | 3 | 4 | 5 | Next >>
|
.gif)
